Reneo Pharma CBO Wendy Johnson to depart Dec 31, enters consulting agreement

OnKure Therapeutics, Inc.

Wendy Johnson will cease as CBO on Dec 31, 2021; will serve as consultant for 18 months.
Severance of $100k contingent on release of claims; continues base salary of $365k/yr until separation.
Equity awards continue to vest during consulting period; full acceleration if Company terminates without cause before June 30, 2023.
Cash consulting fee of $10k/month plus hourly rate for over 32 hours/month.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Wendy Johnson

Chief Business Officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2021-12-31
Filed: December 27, 2021, 6:59 PM ET

On December 23, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) entered into a Transition, Separation and Consulting Agreement (the “Agreement”) with Wendy Johnson, in connection with her previously announced resignation from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy Johnson resigned as Chief Business Officer at OnKure Therapeutics, Inc..

Action: resigned
Role: Chief Business Officer

Exact text from the filing

On December 23, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) entered into a Transition, Separation and Consulting Agreement (the “Agreement”) with Wendy Johnson, in connection with her previously announced resignation from the Company.

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-367001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.